1-3 of 3
Michael Kunz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90 Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT).

Kathleen Gondek, Sonalee Shah, Angelika Bischof-Delaloye, Ama Rohatiner, Gilles Salles, Barbara Putz, Michael Kunz, Anton Hagenbeek
Journal: Blood
Blood (2007) 110 (11): 3319.
https://doi.org/10.1182/blood.V110.11.3319.3319
Published: 2007
Journal Articles

Radioimmunotherapy with 90 Y-Ibritumomab Tiuxetan (Zevalin®) as Consolidation of First Remission in Patients with Advanced Stage Follicular Lymphoma: A ’Real-Time’ MBR RQ-PCR Analysis.

Lindsey Goff, Karin Summers, Sameena Iqbal, Jens Kuhlmann, Michael Kunz, Anton Hagenbeek, Andrew Lister, Ama Rohatiner
Journal: Blood
Blood (2007) 110 (11): 3412.
https://doi.org/10.1182/blood.V110.11.3412.3412
Published: 2007
Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.

Anton Hagenbeek, Angelika Bischof-Delaloye, John A. Radford, Ama Rohatiner, Gilles Salles, Achiel Van Hoof, Barbara Putz, Michael Kunz, Franck Morschhauser
Journal: Blood
Blood (2007) 110 (11): 643.
https://doi.org/10.1182/blood.V110.11.643.643
Published: 2007